Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Amyloidosis × Biological Assay × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Immunoglobulin Light-chain Amyloidosis 1 Amyloidosis 1

Interventions

Dexamethasone 2 venetoclax 1 selinexor 1 daratumumab 1 In Situ Hybridization, Fluorescence 1 In Situ Hybridization 1 Calcium Dobesilate 1 Biological Assay 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05486481 2025-03-06

Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)

University of California, San Francisco

Phase 1/2 Withdrawn

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡